Navigation Links
Boston Biomedical Research Institute Maintains Baa3 Rating from Moody's
Date:3/25/2008

WATERTOWN, Mass., March 25 /PRNewswire/ -- Boston Biomedical Research Institute (BBRI) in Watertown, Massachusetts, was once again given a Baa3 bond rating with a stable outlook by Moody's Investor Services, affirming the Institute's financial stability in an era of declining NIH funding within an overall precarious economy that have left some similar organizations struggling to survive. "We are pleased with this confirmation of our financial health," says BBRI Director and Senior Staff Scientist Charlie Emerson, who adds that the Institute's research efforts continue to be robust and growing.

Boston Biomedical Research Institute is an independent, non-profit research institution devoted to increasing understanding of the causes, prevention and treatment of such diseases as heart disease, cancer, muscular dystrophy and Alzheimer's. Researchers at BBRI look at theses diseases at the biochemical and cellular level to unravel the mysteries of these diseases at their most rudimentary.

Moody's Investor Services, which is one of the two foremost credit rating organizations in the US, reported that: "The stable outlook reflects our expectation that BBRI's management is focused on containment of operating expenses and generation of new revenue streams in light of slowed federal research funding. We believe that the Institute's largely unrestricted financial resource base provides a good cushion for near-term operating pressure." The report added that " ... debt service reserve fund, security interest in gross receipts, and the first mortgage on the research facility provide some additional bondholder security."

According to Dr. Emerson, "Our commitment to diversify our streams of revenue is reflected in the hiring of a new director of advancement and in our decision to enhance board support, increase submissions to private foundations, increase planned giving, and pursue potential state funding, as possible supplemental funding resources."

Among the Institute's scientific breakthroughs have been research that paved the way for the Troponin Assay, one of the standard tests now used by physicians to determine whether a person is having a heart attack and Hyaluronan, essential for eye surgeries and widely used in the treatment of osteoarthritis. Hyaluronan, a carbohydrate polymer that can be injected directly into osteoarthritic joints, may help augment the joint's natural fluids, increasing mobility and shock absorbency.

Founded in 1968, Boston Biomedical Research Institute is a not-for-profit basic research institute dedicated to the understanding, treatment and prevention of a wide range of human diseases and conditions. For more information visit http://www.bbri.org.


'/>"/>
SOURCE Boston Biomedical Research Institute
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
4. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
7. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
8. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
9. Genzyme Begins Major Expansion of Boston Manufacturing Facility
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... ... Scientists at the University of Athens say they have evidence that the ... research that could lead to one good one. Surviving Mesothelioma has just posted an ... The team evaluated 98 mesothelioma patients who got a second kind of ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... Food and Drug Administration (FDA) has granted the company’s orphan drug designation request ... second orphan drug designation granted by the FDA. , Spinocerebellar ataxia is ...
(Date:5/24/2016)... Jolla, CA (PRWEB) , ... May 24, 2016 , ... ... financial planning for corporate executives and entrepreneurs, held The Future of San Diego Life ... in the San Diego life science community attended the event with speakers Dr. Rich ...
(Date:5/23/2016)... ... 23, 2016 , ... PrecisionAg® Media has released its latest ... The paper outlines the key trends that are creating both opportunities and challenges ... lot of highs and lows as the precision agriculture market has grown and ...
Breaking Biology Technology:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/26/2016)... April 27, 2016 Research ... Multi-modal Biometrics Market 2016-2020"  report to their offering.  ... The analysts forecast the global multimodal ... 15.49% during the period 2016-2020.  Multimodal ... sectors such as the healthcare, BFSI, transportation, automotive, ...
Breaking Biology News(10 mins):